



Proteomics International
LABORATORIES LTD

ASX Release

5 June 2025

ASX code: PIQ

Proteomics International completes \$12 million capital raise with significant support for its Share Purchase Plan

- Proteomics International has accepted applications for \$7.5 million via its heavily oversubscribed Share Purchase Plan
- This completes a highly successful \$12 million capital raise following the Institutional and Directors Placement which raised \$4.5 million
- Funds raised will be used to drive and accelerate the launch of the Company's suite of diagnostic tests:
 - PromarkerD for predicting diabetic kidney disease,
 - PromarkerEso for diagnosing esophageal cancer,
 - PromarkerEndo for diagnosing endometriosis, and
 - OxiDx and other pipeline tests

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to announce that it has accepted applications to raise A\$7.5 million in gross proceeds from its Share Purchase Plan [ASX: 5 May] ("SPP"), to complete a highly successful \$12 million capital raise (before costs).

The SPP was massively oversubscribed, and on an upsized basis, has enabled eligible shareholders to purchase approximately 20.3 million new fully paid ordinary shares ("New Shares") at \$0.37 per New Share, and included 1 free attaching option for every 2 New Shares issued ("New Options").

The SPP follows completion of an institutional placement which raised gross proceeds of \$4.0 million [ASX: 22 April] and a Director and Key Management Personnel placement which raised \$0.5m [ASX: 30 May].

Proteomics International Managing Director Dr Richard Lipscombe said, *"We are humbled by the huge vote of confidence from our shareholders who have supported the Share Purchase Plan in large numbers. At this pivotal point in our Company's development, with multiple first-in-class diagnostics going live this year on two continents, these funds enable Proteomics International to expedite commercialisation of the tests and significantly augment our awareness campaigns with consumers (patients, general practitioners, and specialists), advocacy groups and potential partners across the healthcare sector. On behalf of Proteomics International, I would like to thank all our shareholders."*

Use of Funds

The proceeds from the heavily oversubscribed capital raising will be used to accelerate the commercial roll-out of Proteomics International's suite of Promarker diagnostic tests, specifically for:

- Launch and roll-out of three Promarker tests in Australia
- Launch and roll-out of three Promarker tests in USA
- Systems upgrade to provide clinical diagnostic tests in Australia
- Establish laboratory platforms for PromarkerD, PromarkerEso & PromarkerEndo tests in USA
- Progression and launch of pipeline tests including OxiDx
- Working capital & Costs of Offer

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

The issue of New Shares and New Options under the SPP will occur on 6 June 2025. The issue of securities will follow lodgement of a supplementary prospectus for the upsized SPP (to account for the increased number of free attaching New Options).

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe

Managing Director

Proteomics International Laboratories Ltd

T: +61 8 9389 1992

E: enquiries@proteomicsinternational.com

Dirk van Dissel

Investor Relations & Corporate Advisor

Candour Advisory

T: +61 408 326 367

E: dirk@candouradvisory.com.au